(MENAFN- GetNews) (Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Fuchs Dystrophy pipeline constitutes 5+ key companies continuously working towards developing 5+ Fuchs ...

Design Therapeutics (NASDAQ:DSGN) outlined its near-term clinical priorities and key upcoming data readouts during a ...

Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 Cash and Securities of $219.8 Million as of Year-End Supports Ongoing Clinical Execution CARLSBAD, Calif., March 09, 2026 ...

A Conception Bay South man says the estimated five-year wait time for cornea transplants in Newfoundland and Labrador — one of only two provinces without an organ bank for eye tissue — is far too long ...

Researchers report a shift in PK toward high-risk cases as new treatments for corneal ectasia and Fuchs dystrophy reduce low-risk procedures.

Myotonic dystrophy type 1 is a rare, dominantly inherited, progressive, disabling, neuromuscular disease that leads to decreased life expectancy and has no approved therapies. The disease is caused by ...

Christian Fuchs interview: Taking the Newport County role, calling upon Brendan Rodgers and trying to recruit Jamie Vardy Christian Fuchs was on his way to a Premier League title with Leicester City a ...

With Tammy Baisden devoting most of her life to serving Vermillion with kindness, dedication and a willingness to help others ...

Roche’s autoimmune drug Enspryng is making solid progress as a treatment for neuromyelitis optica spectrum disorder (NMOSD). But the company’s efforts to expand its use to a new indication is coming ...

More than 30 rare muscular dystrophy types cause progressive muscle weakness from inherited gene mutations. Combined, they affect about 1 in 5,000 to 8,000 people. Common subtypes vary by age of onset ...

StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models. Gene therapy can effectively treat various ...

PHOENIX — Jace Taylor is a rambunctious 4-year-old boy. He runs, jumps and plays with his friends. He isn’t aware that genetically, he’s different from other children. “I think he’s too young to ...